Your Diagnosis Is a Starting Point, Not Always a Final Answer
When you receive a glioma diagnosis, the pathology report can feel like the last word. A neuropathologist examined your tumor tissue and named what they saw. But today, molecular neuro-oncology means that initial call may not capture the full picture. High-grade gliomas (glioblastoma and anaplastic astrocytoma) contain genetic markers that a traditional microscope review can miss or misidentify. Whether these markers are present changes your diagnosis, prognosis, and treatment options.
This is about understanding that a complete glioma diagnosis requires two parts: the pathologist's examination of the tissue and molecular analysis of the tumor's DNA. If both parts were not done, or your facility doesn't do comprehensive molecular testing, a second pathology opinion is worth considering.
What the 2021 WHO Classification Now Requires
Before 2016, gliomas were classified almost entirely by how they looked under a microscope. Pathologists graded tumors based on cell shape, cell division speed, and abnormal blood vessels. That system had real limits. Two tumors that looked identical under a microscope could behave very differently and respond to different treatments.
The 2016 and 2021 editions of the World Health Organization Classification of Tumors of the Central Nervous System changed that. The 2021 version, called WHO CNS5, made molecular markers a required part of glioma diagnosis. A tumor cannot get its final classification without them. For adult diffuse gliomas, the key markers now include:
- IDH1/2 mutation status: The most important dividing line between molecularly distinct glioma types with different behavior and treatment options.
- MGMT promoter methylation: Predicts response to temozolomide chemotherapy. Our article on how MGMT methylation shapes your treatment plan explains this in detail.
- TERT promoter mutation: When found alongside EGFR amplification or chromosome 7 gain with chromosome 10 loss, it can reclassify what appears to be a lower-grade IDH-wildtype astrocytoma as glioblastoma.
- EGFR amplification: One of three molecular criteria now used to define IDH-wildtype glioblastoma, even when high-grade features are not visible on a slide.
- Chromosome 7 gain and chromosome 10 loss: A hallmark molecular signature of IDH-wildtype glioblastoma under current guidelines.
- 1p/19q co-deletion: Defines oligodendroglioma and carries important implications for chemoradiation sensitivity.
- CDKN2A/B homozygous deletion: In IDH-mutant astrocytoma, this marker signals the highest-grade disease classification (grade 4).
- ATRX mutation: Helps separate astrocytoma from oligodendroglioma when the two look similar under a microscope.
A 2022 analysis comparing diagnostic methods under the WHO CNS5 framework found that next-generation sequencing often works better than standard immunohistochemistry for detecting these markers in routine clinical settings. If your pathology report does not include results for most of the markers above, your molecular profile is incomplete and your diagnosis may need updating.
How Often Do Initial Diagnoses Change After Molecular Review?
The evidence shows this happens regularly. When researchers apply full molecular testing to glioma cases that were initially classified using histology alone or older diagnostic frameworks, a significant portion are reclassified.
A study integrating molecular profiling into glioma diagnosis found that the initial diagnosis changed in 21.2% of patients when WHO 2016 molecular criteria were applied, and in 17.4% under WHO 2021 criteria. These are not small changes. Reclassification can shift a patient from a glioblastoma diagnosis to an IDH-mutant astrocytoma, a tumor with a very different expected course and more treatment options, including IDH inhibitors.
A separate analysis of the TCGA glioma dataset found that 828 of 1,122 glioma cases needed an updated tumor type or diagnosis when WHO CNS5 guidelines were applied. That's more than 73% of a large research cohort requiring some change.
Reclassification does not mean the original pathologist made a mistake. Usually it means the initial workup did not include the full molecular panel now considered standard. Either way, the patient was treated based on incomplete information. Understanding whether your tumor is IDH-mutant or IDH-wildtype, for example, significantly affects prognosis and treatment direction. Our article on IDH-mutant glioma vs. glioblastoma: why your diagnosis type changes everything explains why this distinction matters so much.
What Tests Should Be in Every High-Grade Glioma Workup
If you or a loved one has been diagnosed with a high-grade glioma, check whether these tests were completed. This list reflects what current evidence identifies as necessary in routine clinical practice for accurate glioma classification:
- IDH1 R132H immunohistochemistry plus IDH1/2 sequencing for IDH1-negative tumors in patients under age 55
- MGMT promoter methylation testing (pyrosequencing or methylation-specific PCR)
- TERT promoter mutation analysis
- EGFR amplification (by FISH or next-generation sequencing panel)
- Chromosome 7 gain and chromosome 10 loss (copy number assessment)
- 1p/19q co-deletion, especially for tumors with oligodendroglial histologic features
- ATRX expression by immunohistochemistry
- CDKN2A/B homozygous deletion for IDH-mutant astrocytomas
- H3 K27M or H3 G34 mutation testing for diffuse midline or pediatric-pattern gliomas
A comprehensive molecular panel run on surgical resection tissue (rather than a small needle biopsy core when possible) helps your team understand what they are treating. For a deeper explanation of each test and how results are used clinically, see our overview of what molecular tests your newly diagnosed glioblastoma actually needs and why they matter.
Who Should Consider a Second Pathology Opinion
Not every patient needs a separate neuropathology review, but certain situations make it worth seeking one. The National Brain Tumor Society recommends considering a second opinion before treatment decisions are finalized, especially when the diagnosis is complex or the treating center has limited experience with the specific tumor type.
Consider requesting a pathology review or molecular second opinion if any of the following apply to you:
- You were diagnosed at a community hospital or regional center without a dedicated neuro-oncology program
- Your pathology report carries the qualifier NOS (Not Otherwise Specified), which means incomplete molecular testing
- Your report carries the qualifier NEC (Not Elsewhere Classified), which means testing was done but results didn't fit established diagnostic categories
- Your diagnosis was revised without clear molecular documentation
- You have a grade 3 anaplastic tumor and IDH status or 1p/19q results are missing from the report
- Your report does not document MGMT methylation status
- You are being evaluated for a clinical trial that requires confirmed molecular eligibility criteria
- There is uncertainty about whether your tumor is astrocytoma, oligodendroglioma, or glioblastoma
Major academic cancer centers offer formal second opinion consultations that include pathology review. Memorial Sloan Kettering Cancer Center notes that this typically involves sending tissue samples and imaging records to their specialists for independent review. Pursuing a second opinion does not require transferring your primary care to that center.
What a Pathology Second Opinion Actually Involves
A pathology second opinion is not the same as switching doctors. You can pursue one while continuing to work with your current oncologist. The process generally involves the following steps:
- Request your tissue: Ask your hospital's pathology department to prepare your glass slides and paraffin-embedded tissue block for transfer. This is a standard, routine request. Your samples belong to you.
- Send your records: Include MRI imaging (reports and images on disc), your operative note, and your current pathology and molecular reports along with the tissue.
- Expert neuropathologist review: A specialist at the receiving center examines your slides and molecular data independently of the original diagnosis.
- Tumor board presentation: At many academic centers, complex cases are reviewed at a multidisciplinary brain tumor board, a confidential conference where radiation oncologists, neurosurgeons, neuro-oncologists, and pathologists jointly evaluate the case. The National Brain Tumor Society describes this tumor board process as a key way to ensure a diagnosis has been examined from every expert angle.
Many major centers now offer online second opinion portals. In most cases, you can complete the entire review without traveling to the institution.
Comprehensive Genomic Profiling: Beyond the Standard Panel
Standard pathology panels cover the core markers listed above. Next-generation sequencing, sometimes called comprehensive genomic profiling (CGP), does more. It can screen hundreds of genes at once and detect less common alterations that standard panels might miss: BRAF V600E mutations, NTRK fusions, elevated tumor mutational burden, and rare kinase fusions. Some of these alterations may qualify you for tumor-agnostic therapies or specific clinical trials, regardless of where the cancer started.
Research examining the clinical impact of next-generation sequencing in glioblastoma patients shows that comprehensive sequencing may help refine diagnoses and identify patients who could benefit from targeted or investigational therapies. This field is still developing, and access to CGP varies by center and insurance plan.
CGP is not yet covered for brain tumor patients by all insurers. Before ordering, ask your oncologist whether your situation calls for it and whether your plan will cover it. Some academic centers have patient advocates or financial counselors who can help with coverage for molecular testing.
When to Talk to Your Doctor
If you are unsure whether your pathology report includes a complete molecular panel, print a copy and bring it to your next appointment. Ask specifically whether IDH status, MGMT methylation, TERT promoter mutation, and EGFR amplification were each tested and documented. If any are missing, ask whether they can still be run on existing tissue in the pathology archive.
If your report includes the NOS qualifier, ask your team what additional testing is possible and whether it could change your classification or open new treatment options.
Asking for a second opinion is not an act of distrust. Many oncologists actively encourage it for complex diagnoses. A specialist at an academic neuro-oncology center can either confirm your diagnosis with confidence or find a molecular detail that significantly affects your path forward.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.